Navigation Links
Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
Date:10/8/2007

LONDON, Oct. 9 /PRNewswire/ -- Chiltern, a leading global clinical research organization, has announced the appointment of Steve Albrecht to the role of Director, Business Operations, Late Phase. Steve Albrecht brings over 20 years of CRO industry experience to his new appointment; previously he held executive management positions with other major CROs and recently Registrat in late phase development.

Mr. Albrecht will be providing leadership for the development, implementation and execution of Chiltern's Late Phase strategies.

"I am delighted to join the current excellent staff at Chiltern," said Steve "and I look forward to further developing the Late Phase division in order to provide our sponsors with the best available options for the conduct of their Phase IIIb/IV studies. Post marketing studies pose an excellent opportunity to combine the knowledge gained in early phase development with well-designed and implemented late phase programs. Today, FDA and the pharmaceutical industry are mandating an ever-increasing number of post-marketing trials to follow products in a real-world setting. These studies require high quality standards yielding high quality data."

"I am delighted that Steve has joined Chiltern," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "Steve's strong background in Late Phase will add strength to our group and provide sponsors with services in the design and execution of both commercial programs and risk management programs for their marketed products."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier Richard Baptista

Chiltern International, Inc. Chiltern International Ltd.

2111 Palomar Airport Road 171 Bath Road

Suite 200 Slough

Carlsbad Berkshire

CA 92011 SL1 4AA

USA UNITED KINGDOM

Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000

Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116

Email: Catherine.Lemercier@chiltern.com Email:

Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Steve Tyler Tells All About His Beauty Regime
2. Prince Charles lends support to Alternative Medicine
3. Support therapy helps breast cancer patients
4. Evidence supporting H.pylori eradication
5. Further support for use of statins in Alzheimer’s disease
6. Toxin injections support stroke associated spasticity
7. Support for patients with Leg Pain
8. Vitamin E supports Female Hearts
9. Injection supports Heart Devices
10. Modified antibiotic may support fight cancer
11. WHO To Support Public Health Threats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology: